Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.77 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.62 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30306122 | 1.00 | CYP19A1 (0.77) | CYP19A1KCNA5KCNH2ALOX12MEN1 | |
| SCHEMBL2948643 | 0.88 | CYP19A1 (0.77) | CYP19A1KCNA5KCNH2ALOX12MEN1 | |
| SCHEMBL2948668 | 0.88 | CYP19A1 (0.81) | CYP19A1KCNA5KCNH2MEN1KMT2A | |
| SCHEMBL2945797 | 0.87 | CYP19A1 (1.00) | CYP19A1KCNA5KCNH2MEN1KMT2A | |
| SCHEMBL30589551 | 0.87 | CYP19A1 (1.00) | CYP19A1KCNA5KCNH2MEN1KMT2A | |
| SCHEMBL2952139 | 0.87 | ALOX12 (0.76) | CYP19A1KCNA5KCNH2ALOX12MEN1 | |
| SCHEMBL2953798 | 0.85 | CYP19A1 (0.81) | CYP19A1KCNA5KCNH2MEN1KMT2A | |
| SCHEMBL13234493 | 0.85 | CYP19A1 (0.85) | CYP19A1KCNA5KCNH2MEN1KMT2A | |
| SCHEMBL2949291 | 0.85 | CYP19A1 (0.81) | CYP19A1KCNA5KCNH2MEN1KMT2A | |
| SCHEMBL29963707 | 0.85 | CYP19A1 (0.81) | CYP19A1KCNA5KCNH2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630779-B1 | ANTIBIOTIC RESISTANCE BREAKERS | KING S COLLEGE LONDON (GB) | 2025-09-03 | — | — | EP | disclosed |
| US-11746116-B2 | Antibiotic resistance breakers | KING'S COLLEGE LONDON (GB) | 2023-09-05 | — | — | US | disclosed |
| US-11746116-B2 | Antibiotic resistance breakers | KING'S COLLEGE LONDON (GB) | 2023-09-05 | — | — | US | disclosed |
| US-11746116-B2 | Antibiotic resistance breakers | KING'S COLLEGE LONDON (GB) | 2023-09-05 | — | — | US | disclosed |
| CN-110869373-B | Antibiotic resistance disruptors | 伦敦皇家学院 | 2023-03-07 | — | — | CN | disclosed |
| CN-110869373-A | Antibiotic resistance disruptors | 伦敦皇家学院 | 2020-03-06 | — | — | CN | disclosed |
| US-8026366-B2 | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-09-27 | — | — | US | disclosed |
| US-20070208052-A1 | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-09-06 | — | — | US | disclosed |
| WO-2006009826-A1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-01-26 | — | — | WO | disclosed |
| EP-1109560-B1 | COMPOUNDS USEFUL AS AICARFT INHIBITORS | AGOURON PHARMA (US) | 2003-08-27 | — | — | EP | disclosed |
| US-6525050-B1 | Inhibit the enzyme aminoimidazole carboxamide ribonucleotide formyl transferase; antiproliferative agents; antitumor, antiinflammatory, antipsoriatic, and/or immunosuppressive | AGOURON PHARMACEUTICALS, INC. | 2003-02-25 | — | — | US | disclosed |
| EP-1109560-A4 | COMPOUNDS USEFUL AS AICARFT INHIBITORS | AGOURON PHARMA (US) | 2002-04-17 | — | — | EP | disclosed |
| EP-1109560-A1 | COMPOUNDS USEFUL AS AICARFT INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000013688-A1 | COMPOUNDS USEFUL AS AICARFT INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746116-B2 | Antibiotic resistance breakers | ABCC1, ARL1, AKR1C3 | CYP19A1 176/4885KCNA5 2999/4885KCNH2 3591/4885 |
| US-20070208052-A1 | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines | IL2, TSLP, IFNG | CYP19A1 3280/4885KCNA5 4650/4885KCNH2 4137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.